
Opinion|Videos|February 5, 2025
Treatment and Co-Management of mCRPC Patients with Aggressive Disease
Author(s)Jose De La Cerda III, MD, MPH
This video segment explores treatment approaches for PSMA-positive mCRPC patients, algorithms for monitoring liver dysfunction in advanced CRPC, and exciting advancements in mCRPC treatment.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- If the patient is positive for prostate-specific membrane antigen (PSMA), how would you treat the patient?
- What is your algorithm for monitoring patients with liver dysfunction and advanced CRPC?
- What advances in treatment of mCRPC are you most excited about?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants 510(k) clearance to Break Wave lithotripsy device for kidney stones
2
CaverSTIM device shows initial promise for post-prostatectomy erectile dysfunction
3
Study launches of MRI plus PSMA-PET imaging for prostate cancer detection
4
John Sfakianos, MD, on moving immunotherapy earlier in NMIBC treatment pathway
5


















